Compare CTRI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | SRPT |
|---|---|---|
| Founded | 1909 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2024 | 2000 |
| Metric | CTRI | SRPT |
|---|---|---|
| Price | $33.45 | $20.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 29 |
| Target Price | ★ $29.88 | $25.85 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $2,982,781,000.00 | $2,198,237,000.00 |
| Revenue This Year | $14.62 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $166.16 | ★ N/A |
| Revenue Growth | 13.10 | ★ 15.58 |
| 52 Week Low | $18.59 | $10.42 |
| 52 Week High | $42.99 | $44.14 |
| Indicator | CTRI | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 46.98 |
| Support Level | $32.34 | $16.09 |
| Resistance Level | $34.10 | $23.31 |
| Average True Range (ATR) | 1.66 | 1.13 |
| MACD | 0.18 | -0.04 |
| Stochastic Oscillator | 8.84 | 40.90 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.